Guides
Plain-language explainers on access routes, reimbursement and how to choose a provider. Every guide is informational self-assessment material — the eligibility check itself always happens with a clinician.
Where in Europe Can You Actually Get Psychedelic Therapy in 2026?
Compared for 2026: esketamine is reimbursed in 13 European countries, private ketamine clinics are legal in 7, psilocybin therapy exists in 3 (Switzerland, Germany, Czechia) and MDMA therapy in Switzerland only — plus what travelling for treatment involves.
Country access guides
Psychedelic Therapy in Austria: Every Legal Route in 2026
Every legal route to psychedelic therapy in Austria in 2026: how Spravato is funded through hospital stays and case-by-case approvals, Vienna's private esketamine practices and their prices, and the research-only status of psilocybin and MDMA.
Psychedelic Therapy in Belgium: Every Legal Route in 2026
Every legal route to psychedelic therapy in Belgium in 2026: Spravato reimbursed since 2021 with per-patient prior authorization, hospital-based off-label ketamine, and two recruiting psilocybin trials in Ghent and Brussels.
Psychedelic Therapy in Croatia: Every Legal Route in 2026
All legal routes to psychedelic-adjacent therapy in Croatia in 2026: Spravato funded through HZZO's especially-expensive-drugs list, hospital psychiatry in Zagreb, private ketamine therapy in Split, a recruiting esketamine study, and the research-only status of psilocybin and MDMA.
Psychedelic Therapy in Cyprus: Every Legal Route in 2026
Medical ketamine and esketamine therapy for depression in Cyprus in 2026: no confirmed GESY coverage, so the working route is private intramuscular ketamine treatment at the Cyprus rTMS centre in Nicosia. This guide covers licensed depression treatment, not addiction rehabilitation services.
Psychedelic Therapy in Czechia: Every Legal Route in 2026
All four legal routes to psychedelic therapy in Czechia in 2026: reimbursed Spravato, partially covered ketamine-assisted psychotherapy, the completed psilocybin framework with its real rollout status and first named sites, and MDMA's research-only reality.
Psychedelic Therapy in Denmark: Every Legal Route in 2026
All the legal routes to psychedelic therapy in Denmark in 2026: newly recommended Spravato for treatment-resistant depression, the acute-care route for admitted patients, Copenhagen's strong research scene, and honest guidance on what private offers can legally include.
Psychedelic Therapy in Estonia: Every Legal Route in 2026
All legal routes to psychedelic therapy in Estonia in 2026: Spravato is registered but has no confirmed public reimbursement, so the working route is private esketamine treatment at Tallinn's Marienthali Kliinik with published prices — while psilocybin and MDMA remain research-only.
Psychedelic Therapy in Finland: Every Legal Route in 2026
All legal routes to psychedelic therapy in Finland in 2026: Kela-reimbursed Spravato under Europe's strictest criteria, the unique pharmacy-dispensing model that allows supervised outpatient treatment, and the honest research-only status of psilocybin and MDMA.
Psychedelic Therapy in France: Every Legal Route in 2026
France is hospital-only for ketamine and Spravato (esketamine): who qualifies, how hospital referral works, the March 2026 ANSM framework and which trials recruit. Guides en français inclus.
Psychedelic Therapy in Germany: Every Legal Route in 2026
Are psychedelics legal in Germany? The 2026 picture: GKV-covered Spravato, private ketamine at €200–400 per session, the two-site psilocybin compassionate use program, and MDMA's research-only status under Anlage I BtMG.
Psychedelic Therapy in Hungary: Every Legal Route in 2026
All legal routes to psychedelic-adjacent therapy in Hungary in 2026: publicly supported Spravato delivered through hospital psychiatry, private ketamine infusion therapy in Budapest, a recruiting esketamine trial in three cities, and the research-only status of psilocybin and MDMA.
Psychedelic Therapy in Ireland: Every Legal Route in 2026
All the legal routes to psychedelic therapy in Ireland in 2026: HSE-reimbursed Spravato through specialist psychiatric services, the honest state of the private market, and Ireland's psilocybin research scene from Tallaght to Galway.
Psychedelic Therapy in Italy: Every Legal Route in 2026
All the legal routes to psychedelic therapy in Italy in 2026: Spravato reimbursed as a hospital medicine at regionally authorized centers, the small private ketamine market, the research-only reality of psilocybin and MDMA, and the trials recruiting now.
Psychedelic Therapy in Latvia: Every Legal Route in 2026
All legal routes to psychedelic therapy in Latvia in 2026: the Baltics' only state-paid esketamine programme at the National Mental Health Centre in Riga — how the doctors' council route works, what the state pays, and the honest research-only status of psilocybin and MDMA.
Psychedelic Therapy in Lithuania: Every Legal Route in 2026
All legal routes to psychedelic therapy in Lithuania in 2026: Spravato is registered but reimbursement is unconfirmed, so the working route is private ketamine treatment at Vilnius's Noos klinika — the first KIT and KAP provider in the Baltics — while psilocybin and MDMA remain research-only.
Psychedelic Therapy in the Netherlands: Every Legal Route in 2026
All legal routes to psychedelic therapy in the Netherlands in 2026: basic-package Spravato at ENC-NL centers, hospital (es)ketamine and the oral esketamine research, psilocybin and MDMA's research-only reality, and why truffle retreats are not medical care.
Psychedelic Therapy in Norway: Every Legal Route in 2026
All legal routes to psychedelic therapy in Norway in 2026: the world-first publicly funded IV ketamine pathway for treatment-resistant depression, how the fastlege-to-DPS referral actually works, private ketamine clinics in Oslo, and the honest status of psilocybin and MDMA.
Psychedelic Therapy in Poland: Every Legal Route in 2026
All legal routes to psychedelic therapy in Poland in 2026: free esketamine through NFZ drug program B.147, private ketamine clinics in Warsaw and Wrocław, and the research-only reality of psilocybin and MDMA.
Psychedelic Therapy in Portugal: Every Legal Route in 2026
All the legal routes to psychedelic therapy in Portugal in 2026: hospital-financed Spravato under strict INFARMED criteria, Lisbon's private ketamine-assisted psychotherapy clinics with published prices, and the honest research-only status of psilocybin and MDMA.
Psychedelic Therapy in Romania: Every Legal Route in 2026
All legal routes to psychedelic-adjacent therapy in Romania in 2026: the CNAS national subprogram that funds esketamine at Bucharest's Obregia hospital, why the 2020 HTA kept Spravato off the standard reimbursement list, and the research-only status of ketamine, psilocybin and MDMA.
Psychedelic Therapy in Slovakia: Every Legal Route in 2026
All legal routes to psychedelic-adjacent therapy in Slovakia in 2026: why the NIHO assessment kept Spravato off public reimbursement, the insurer-exception mechanism, the private options that remain, and the research-only status of psilocybin and MDMA.
Psychedelic Therapy in Spain: Every Legal Route in 2026
Ketamine therapy in Spain in 2026: private clinics in Barcelona, Madrid and Mallorca and what full programs cost, publicly financed Spravato for treatment-resistant depression, and psilocybin and MDMA's research-only status.
Psychedelic Integration Support in Spain: What Exists and What Is Legal in 2026
Looking for a psychedelic integration therapist in Madrid or Barcelona? What integration support legally exists in Spain, how to verify a licensed psychologist through the colegio registries, and where the medical routes are.
Psychedelic Therapy in Sweden: Every Legal Route in 2026
All legal routes to psychedelic therapy in Sweden in 2026: why Spravato is legal but deliberately held back by the NT Council, off-label ketamine in specialist and private settings, and the recruiting psilocybin trials in five Swedish cities.
Psychedelic Therapy in Switzerland: Every Legal Route in 2026
All four legal routes to psychedelic therapy in Switzerland in 2026: Spravato at the 52 BAG-designated centers, the limited medical use program for psilocybin, LSD and MDMA, private ketamine, and clinical trials.
Psychedelic Therapy in the UK: Every Legal Route in 2026
All the legal routes to psychedelic therapy in the UK in 2026: why NHS esketamine is closed in England but open in Scotland, private ketamine clinic costs, and the honest status of psilocybin and MDMA research.
Ketamine Therapy in Scotland: NHS and Private Options (2026)
Scotland is the one UK nation where the NHS funds Spravato. What that route involves, what private ketamine costs in Edinburgh and Glasgow, and where the trials are.
Ketamine Treatment in the UK: NHS Routes vs Private Clinics (2026)
Private London clinics charge around £595 per ketamine infusion; an NHS trust in Oxford charges £265. How the NHS routes actually work, who qualifies for funded treatment, what private clinics bundle for the difference, and when a trial beats both.
Europe-wide guides
How to Choose a Ketamine or KAP Clinic in Europe: Licenses, Red Flags and Fair Prices
What 'licensed' actually means in each country, the warning signs that should make you walk away, realistic 2026 price ranges, and the questions to ask before booking.
Joining a Psychedelic Clinical Trial in Europe: How It Works in 2026
Phases, placebo and consent explained, why most applicants are screened out, which sponsors are recruiting across Europe in 2026, and how to search the registries.
For Clinicians: Referring a Patient to Psychedelic Medicine in Europe
An informational summary for GPs and psychiatrists: when treatment-resistant depression opens the esketamine route, what documentation receiving centers need, country-specific referral mechanics, trials as a referral option, and how this directory's registry verification works.
How to Help a Loved One Consider Psychedelic Therapy
A practical guide for family members and partners: how to recognize when standard depression treatment is not working, how to talk about psychedelic therapy without pushing, the documents that genuinely help, and what to do in a crisis.
Insurance & Reimbursement for Psychedelic Medicine in Europe: The 2026 Country Map
Which European countries reimburse esketamine (Spravato), ketamine and psychedelic therapy in 2026, under what criteria, who decides — and the exceptional pathways most patients never hear about.
Is Ketamine a Psychedelic? The Classification, and Why It Matters
Ketamine is a dissociative anaesthetic, not a classic psychedelic — but it is treated as one in practice. What that means for legality, evidence and access in Europe.
Is Ketamine Therapy Legal? The European Picture in 2026
Ketamine therapy is legal across Europe when a doctor prescribes it off-label — but legal, available and funded are three different things. The rules by country.
Esketamine and Ketamine Therapy in Scandinavia: Norway, Sweden, Denmark, Finland
How Norway, Sweden, Denmark and Finland handle esketamine and ketamine therapy in 2026: who funds what, the private market, recruiting trials — compared side by side.
How to Prepare for Ketamine Therapy: A Practical Checklist
What to do before, during and after ketamine or esketamine treatment: what to prepare, what screening covers, how a session day runs and what aftercare should include.
Does it work? The evidence
Esketamine (Spravato): What the Evidence Shows
An evidence review of esketamine nasal spray (Spravato) for depression in Europe: the approved indication, pivotal trials (TRANSFORM, SUSTAIN, ESCAPE-TRD), the suicidal-ideation question, safety, and how EU access works.
Ketamine for Depression: What the Evidence Shows
An evidence review of racemic ketamine for depression in Europe: the IV infusion evidence base, single vs repeated infusions, meta-analyses, ketamine-assisted psychotherapy, off-label reality, and Norway's public-funding milestone.
MDMA-Assisted Therapy: What the Evidence Shows
An honest, tiered look at the MDMA-assisted therapy evidence base for PTSD in 2026: the two Phase 3 trials, the FDA's 2024 rejection and what it means for Europe, safety, and how access actually works.
Psilocybin Therapy: What the Evidence Shows
An honest, tiered look at the psilocybin evidence base in 2026: the Phase 3 depression results, what is still early, safety and exclusion criteria, and how legal access actually works in Europe.
Spravato (Esketamine) vs Ketamine Infusions: The Practical Differences
How Spravato (esketamine) differs from ketamine infusions in Europe: approval, setting, monitoring, insurance and cost, plus where each is available.
Reimbursement by country
One question per page: is esketamine (Spravato) — or, in Norway's case, ketamine — publicly covered, for whom, and at what cost. Start from the Europe-wide reimbursement map if you want the comparison first.